Biotechnology Analyst, CFA. Cancer, Autoimmune and Neurodegenerative Diseases. Audaces fortuna iuvat.
Texas
Joined April 2009
- Tweets8K
- Following577
- Followers1.6K
- Likes79
CEO Dr. James Bianco identifies some of the conferences where @TuhuraBio may present its ADC-Delta Opioid Receptor data over the next several months.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/AluiFQ2Ps…
Actinium presentation starting now!
@ActiniumPharma discloses ATNM400 target as HER3
*To present first in human clinical data in mCRPC @ EANM 19Oct, 10:45 ET
*Includes safety, biodistribution, dosimetry & serial PET assessment of tumor uptake and clearance, to inform development & dosing of $ATNM 400
finance.yahoo.com/healthcare…
Zacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/file…
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews
TuHURA CEO Dr. James Bianco looks at next steps for the TBS-2025 program and highlights the NPM1 mutated AML population that will be enrolled in the upcoming Phase Ib trial. $HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/Az3gDNST3…
TBS 2025 Next Steps
TuHURA CEO Dr. James Bianco looks at next steps for the TBS-2025 pr...
youtube.comUS Patent Office issues patent to @TuhuraBio
*Anti-VISTA Antibodies & Uses Thereof
*IP for use as single agent or in combination
*Extends beyond cancer
*Term to 18Feb42
*Complements upcoming Ph1b TBS2025 trial
$HURA
finance.yahoo.com/healthcare…
Tuhura Bio CEO Dr. James Bianco looks at next steps for the TBS-2025 program and highlights the NPM1 mutated AML population that will be enrolled in the upcoming Phase Ib trial.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/Az3gDNST3…
Spectral AI's DeepView showcased @ American College of Emergency Physicians (ACEP) Scientific Assembly
*5-8Oct
*Chicago
*Can engage with emergency dept personnel & introduce DeepView
$MDAI
finance.yahoo.com/healthcare…
US Patent Office issues patent to @TuhuraBio
*Anti-VISTA Antibodies & Uses Thereof
*IP for use as single agent or in combination
*Extends beyond cancer
*Term to 18Feb42
*Complements upcoming Ph1b TBS2025 trial
$HURA
finance.yahoo.com/healthcare…
CEO Dr. James Bianco provides background to the patent announcement earlier today. He introduces @TuHURA’s ADC program and explains how it can address immunosuppressive MDSCs and block the VISTA checkpoint inhibitor.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/rT1RLh6db8Y
@HURA_IR receives patent for Delta Opioid Receptor & Antibody Drug Conjugate technology
*#12,734,168-Delta Opioid Receptor Antagonists Reprogram Immunosuppresive Microenvironment to Boost Immunotherapy
*2043 patent expiry before PTE
$HURA
finance.yahoo.com/healthcare…
If @TuhuraBio is successful with its deep-seated tumor trial in Merkel cell carcinoma, it could expand IFx-2.0's addressable market by 30%. Join CEO Dr. James Bianco as he explains.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/vl5dwhBbF…
Azitra's ATR04 completes 1st cohort in its Ph1/2 trial for EGFRi rash
*Safety committee clears for cohort 2 start
*Study being done @ 6 sites
ir.azitrainc.com/news-releas…
See our recent $AZTR report w/ updated valuation: s27.q4cdn.com/906368049/file…
Achieve Life Sciences appoints Benjamin Halladay as CFO
*Will lead $ACHV's financial strategy, accounting, investor relations & information technology
*Joins from Esperion Therapeutics & brings deal experience
*Prior roles @ $PFE & the oil patch
ir.achievelifesciences.com/n…
Nasus Pharma enrolls & doses 1st patient in Ph1 study of NS003-intranasal ondansetron-for nausea & vomiting
*Topline expected 4Q26
*Oral & injectable administration present shortcomings that NS003 may address & may improve rapidity of onset.
$NSRX
ir.nasuspharma.com/press_rel…
Zacks' Senior Life Sciences Analyst John Vandermosten initiates on #ActiniumPharmaceuticals with a $4.00 price target.
youtube.com/shorts/Gh-GBsZux…
Initiation: tinyurl.com/bdj6rjtm
$ATNM #NuclearMedicine #Radiopharmaceuticals #Oncology #AML #TargetedRadiotherapy #Biotech #CancerResearch
Cardiff Oncology resolves dispute with Nerviano
*2017 agreement amended
~includes development objectives
~NMS may appoint board observer & join scientific advisory board
*Full & mutual release of claims
$CRDF
finance.yahoo.com/healthcare…
8K:
investors.cardiffoncology.co…
Earlier today, @TuhuraBio announced that the FDA had cleared its IND for TBS-2025. Join CEO Dr. James A. Bianco, MD as he explains the rationale behind pursuing VISTA.
youtube.com/shorts/HJb6JOru9…
$HURA #ImmunoOncology #CancerResearch #LifeSciences
ir.tuhurabio.com/news-events…
FDA clears pivotal study for Nasus Pharma's NS002
*Trial to start in 4Q26
*Topline readout 1Q27
*To evaluate intranasal epinephrine powder as a needle-free alternative to EpiPen
$NSRX
finance.yahoo.com/healthcare…
Lexaria warrant exercise yields $5.9mm
*Exercise price reduced to $12.92/share
*~454k shares
*Close expected 9Sep
$LEXX
finance.yahoo.com/markets/st…
Nasus Pharma to present @ HC Wainwright
*14-16 Sept
*NYC
*CEO Brendan O'Grady & CFO Eyal Rubin attending
$NSRX
finance.yahoo.com/healthcare…
Chief Operating Officer, Joe Hazelton, explains how the increase in demand for protein rich foods expands the markets that @DyadicInc can serve.
#Biotechnology #Biomanufacturing #LifeSciences #AlternativeProteins #PrecisionFermentation
$DYAI
youtube.com/shorts/kflxvuMHj…
President & Chief Operating Officer, Joe Hazelton, discusses the many different end markets that @DyadicInc can serve.
#Biotechnology #Biomanufacturing #LifeSciences #AlternativeProteins #PrecisionFermentation
$DYAI
youtube.com/shorts/hd-AbPtmn…
